These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 16648575)

  • 1. Cytokines fused to antibodies and their combinations as therapeutic agents against different peritoneal HER2/neu expressing tumors.
    Helguera G; Rodríguez JA; Penichet ML
    Mol Cancer Ther; 2006 Apr; 5(4):1029-40. PubMed ID: 16648575
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vaccination with novel combinations of anti-HER2/neu cytokines fusion proteins and soluble protein antigen elicits a protective immune response against HER2/neu expressing tumors.
    Helguera G; Dela Cruz JS; Lowe C; Ng PP; Trinh R; Morrison SL; Penichet ML
    Vaccine; 2006 Jan; 24(3):304-16. PubMed ID: 16125282
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recombinant anti-human HER2/neu IgG3-(GM-CSF) fusion protein retains antigen specificity and cytokine function and demonstrates antitumor activity.
    Dela Cruz JS; Trinh KR; Morrison SL; Penichet ML
    J Immunol; 2000 Nov; 165(9):5112-21. PubMed ID: 11046042
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term immunity elicited by antibody-cytokine fusion proteins protects against sequential challenge with murine mammary and colon malignancies.
    Helguera G; Rodríguez JA; Daniels TR; Penichet ML
    Cancer Immunol Immunother; 2007 Sep; 56(9):1507-12. PubMed ID: 17310381
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-HER2/neu IgG3-(IL-2) and anti-HER2/neu IgG3-(GM-CSF) promote HER2/neu processing and presentation by dendritic cells: implications in immunotherapy and vaccination strategies.
    Dela Cruz JS; Trinh KR; Chen HW; Ribas A; Morrison SL; Penichet ML
    Mol Immunol; 2006 Feb; 43(6):667-76. PubMed ID: 15908002
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antitumor activity of a dual cytokine/single-chain antibody fusion protein for simultaneous delivery of GM-CSF and IL-2 to Ep-CAM expressing tumor cells.
    Schanzer JM; Fichtner I; Baeuerle PA; Kufer P
    J Immunother; 2006; 29(5):477-88. PubMed ID: 16971804
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bi-functional cytokine fusion proteins for gene therapy and antibody-targeted treatment of cancer.
    Gillies SD; Lan Y; Brunkhorst B; Wong WK; Li Y; Lo KM
    Cancer Immunol Immunother; 2002 Oct; 51(8):449-60. PubMed ID: 12202906
    [TBL] [Abstract][Full Text] [Related]  

  • 8. IL-12 enhances the antitumor actions of trastuzumab via NK cell IFN-γ production.
    Jaime-Ramirez AC; Mundy-Bosse BL; Kondadasula S; Jones NB; Roda JM; Mani A; Parihar R; Karpa V; Papenfuss TL; LaPerle KM; Biller E; Lehman A; Chaudhury AR; Jarjoura D; Burry RW; Carson WE
    J Immunol; 2011 Mar; 186(6):3401-9. PubMed ID: 21321106
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanism of antitumor activity of a single-chain interleukin-12 IgG3 antibody fusion protein (mscIL-12.her2.IgG3).
    Peng LS; Penichet ML; Dela Cruz JS; Sampogna SL; Morrison SL
    J Interferon Cytokine Res; 2001 Sep; 21(9):709-20. PubMed ID: 11576465
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A recombinant IgG3-(IL-2) fusion protein for the treatment of human HER2/neu expressing tumors.
    Penichet ML; Dela Cruz JS; Shin SU; Morrison SL
    Hum Antibodies; 2001; 10(1):43-9. PubMed ID: 11455061
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Protein vaccination with the HER2/neu extracellular domain plus anti-HER2/neu antibody-cytokine fusion proteins induces a protective anti-HER2/neu immune response in mice.
    Dela Cruz JS; Lau SY; Ramirez EM; De Giovanni C; Forni G; Morrison SL; Penichet ML
    Vaccine; 2003 Mar; 21(13-14):1317-26. PubMed ID: 12615426
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Insights into the mechanism of anti-tumor immunity in mice vaccinated with the human HER2/neu extracellular domain plus anti-HER2/neu IgG3-(IL-2) or anti-HER2/neu IgG3-(GM-CSF) fusion protein.
    Dela Cruz JS; Morrison SL; Penichet ML
    Vaccine; 2005 Sep; 23(39):4793-803. PubMed ID: 15967544
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vivo properties of three human HER2/neu-expressing murine cell lines in immunocompetent mice.
    Penichet ML; Challita PM; Shin SU; Sampogna SL; Rosenblatt JD; Morrison SL
    Lab Anim Sci; 1999 Apr; 49(2):179-88. PubMed ID: 10331548
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of implanted mammary tumors with recombinant vesicular stomatitis virus targeted to Her2/neu.
    Bergman I; Griffin JA; Gao Y; Whitaker-Dowling P
    Int J Cancer; 2007 Jul; 121(2):425-30. PubMed ID: 17354238
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synergistic anti-tumor effects with co-expression of GM-CSF and IFN-gamma in murine tumors.
    Yoon SJ; Heo DS; Kang JO; Lee SG; Kim CD; Sung MW; Kim NK
    Int J Cancer; 1998 Sep; 77(6):907-12. PubMed ID: 9714062
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunotherapeutic intervention with oncolytic adenovirus in mouse mammary tumors.
    Gibson H; Munns S; Freytag S; Barton K; Veenstra J; Bettahi I; Bissonette J; Wei WZ
    Oncoimmunology; 2015 Jan; 4(1):e984523. PubMed ID: 25949865
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Polymalic acid nanobioconjugate for simultaneous immunostimulation and inhibition of tumor growth in HER2/neu-positive breast cancer.
    Ding H; Helguera G; Rodríguez JA; Markman J; Luria-Pérez R; Gangalum P; Portilla-Arias J; Inoue S; Daniels-Wells TR; Black K; Holler E; Penichet ML; Ljubimova JY
    J Control Release; 2013 Nov; 171(3):322-9. PubMed ID: 23770212
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen.
    Ojima T; Iwahashi M; Nakamura M; Matsuda K; Naka T; Nakamori M; Ueda K; Ishida K; Yamaue H
    Int J Oncol; 2006 Apr; 28(4):947-53. PubMed ID: 16525645
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cancer immunotherapy with interleukin 12 and granulocyte-macrophage colony-stimulating factor-encapsulated microspheres: coinduction of innate and adaptive antitumor immunity and cure of disseminated disease.
    Hill HC; Conway TF; Sabel MS; Jong YS; Mathiowitz E; Bankert RB; Egilmez NK
    Cancer Res; 2002 Dec; 62(24):7254-63. PubMed ID: 12499267
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic effects of idiotype vaccination can be enhanced by the combination of granulocyte-macrophage colony-stimulating factor and interleukin 2 in a myeloma model.
    Stritzke J; Zunkel T; Steinmann J; Schmitz N; Uharek L; Zeis M
    Br J Haematol; 2003 Jan; 120(1):27-35. PubMed ID: 12492573
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.